ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
Dow Jones
42.732,13
0,80%
Euro vs US Dollar
1,03115
0,00%
Bitcoin
98.321,70
0,12%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Marinus Pharmaceuticals Inc (MRNS)

  7. Marinus Pharmaceuticals Inc (MRNS) News

MRNS

Marinus Pharmaceuticals (MRNS)

Marinus Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:MRNS
DatumZeitQuelleÜberschriftSymbolFirma
02/01/202521h25Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:MRNSMarinus Pharmaceuticals Inc
02/01/202521h25Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:MRNSMarinus Pharmaceuticals Inc
30/12/202413h11Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:MRNSMarinus Pharmaceuticals Inc
30/12/202413h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
30/12/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
30/12/202413h00Business WireImmedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.NASDAQ:MRNSMarinus Pharmaceuticals Inc
23/12/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
10/12/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
10/12/202421h18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MRNSMarinus Pharmaceuticals Inc
15/11/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
15/11/202400h39Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:MRNSMarinus Pharmaceuticals Inc
14/11/202421h04Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MRNSMarinus Pharmaceuticals Inc
14/11/202418h24Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MRNSMarinus Pharmaceuticals Inc
14/11/202415h34Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MRNSMarinus Pharmaceuticals Inc
12/11/202422h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRNSMarinus Pharmaceuticals Inc
12/11/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
12/11/202422h00Business WireMarinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
02/11/202401h30Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:MRNSMarinus Pharmaceuticals Inc
02/11/202401h30Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:MRNSMarinus Pharmaceuticals Inc
02/11/202401h30Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:MRNSMarinus Pharmaceuticals Inc
24/10/202414h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
24/10/202414h00Business WireMarinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic AlternativesNASDAQ:MRNSMarinus Pharmaceuticals Inc
17/10/202413h00Business WireMarinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual MeetingNASDAQ:MRNSMarinus Pharmaceuticals Inc
15/10/202422h00Business WireMarinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration RegimensNASDAQ:MRNSMarinus Pharmaceuticals Inc
09/10/202413h00Business WireMarinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual MeetingNASDAQ:MRNSMarinus Pharmaceuticals Inc
08/10/202422h04Business WireMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:MRNSMarinus Pharmaceuticals Inc
02/10/202413h56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
20/09/202414h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
20/09/202414h00Business WireMarinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst DayNASDAQ:MRNSMarinus Pharmaceuticals Inc
12/09/202414h00Business WireMarinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024NASDAQ:MRNSMarinus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MRNS

Kürzlich von Ihnen besucht

USOTC
WOEN
Wolf Energy Services (CE)
NASDAQ
MRNS
Marinus Pharmaceuticals
LSE
0UI8
Aptose Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten